AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

CRMP2 SUMOylation- A Biomarker for Chronic Pain

Detailed Technology Description

Title: CRMP2 SUMOylation - A Biomarker for Chronic Pain Invention: This technology pertains to the implementation of CRMP2 SUMOylation as a novel objective biomarker to guide drug development and clinical practice for pain management. Background: The current success rate of treating chronic pain is approximately 30%. Both treatment and research into chronic pain are greatly compromised by the fact that there is no objective biomarker for accurate diagnosis of chronic pain. As of now, pain diagnosis relies heavily on subjective assessment. SUMOylation of CRMP2 is associated to chronic pain and could be used as a measurable biomarker of pain. Applications:Development of an objective biomarker for chronic pain and neuropathic painBiomarker for diagnosis, prediction of pain level, and assessment of treatment efficiency Advantages:Potential to predict pain level and treatment efficiencyCRMP2 SUMOylation regulates Nav1.7 expression, a validated target for chronic pain treatment Potential for use in stratifying patients that would respond to treatments targeting this pathwayPotential for development of a companion diagnostic Licensing Manager:Lisa LinLisaL@tla.arizona.edu(520) 626-6969

Country/Region

USA

For more information, please click Here